Preferred Label : Anti-SARS-CoV-2 Polyclonal Antibodies XAV-19;
NCIt synonyms : Anti-SARS-CoV-2 Spike-protein Polyclonal Antibodies XAV-19; Anti-COVID-19 Spike-protein Polyclonal Antibodies XAV-19; Glyco-humanized Polyclonal Antibodies XAV-19; GH-pAb XAV-19; XAV-19;
NCIt definition : A preparation of hyperimmune heterologous swine glyco-optimized humanized polyclonal
antibodies directed against the spike (S) protein of severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization and protection
against Coronavirus disease 2019 (COVID-19). Upon administration of anti-SARS-CoV-2
polyclonal antibodies XAV-19, the antibodies specifically target and bind to the SARS-CoV-2
S protein, thereby blocking viral attachment and entry into human cells and may thereby
neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate
recovery, and may potentially provide temporary protection against infection with
SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential
role in the infection pathway of the SARS-CoV-2 virus.;
Molecule name : XAV19; XAV 19;
NCI Metathesaurus CUI : CL1407657;
Origin ID : C173855;
UMLS CUI : C5418034;
Currated CISMeF NLP mapping
- XAV-19 [MeSH Supplementary Concept]
Semantic type(s)
UMLS correspondences (same concept)
- XAV-19 [MeSH Supplementary Concept]
concept_is_in_subset
https://www.has-sante.fr/jcms/p_3312591/fr/xav-19-immunoglobuline-g-porcine-anti-sars-cov-2
https://www.has-sante.fr/jcms/p_3312597/fr/decision-n-2022-0029/dc/sem-du-27-janvier-2022-du-college-de-la-haute-autorite-de-sante-portant-refus-de-la-demande-d-autorisation-d-acces-precoce-de-la-specialite-xav-19
2022
false
false
false
France
Anti-SARS-CoV-2 Polyclonal Antibodies XAV-19
COVID-19
antibodies, heterophile
SARS Coronavirus 2 Antibody
insurance, health, reimbursement
treatment outcome
oxygen inhalation therapy
infusions, intravenous
evaluation of the transparency committee
SARS-CoV-2
XAV-19
---